Pfizer (NYSE:PFE) Trading 1.4% Higher – Here’s Why

Pfizer Inc. (NYSE:PFE) shares were up 1.4% on Wednesday . The stock traded as high as $27.49 and last traded at $27.4710. Approximately 32,860,882 shares traded hands during trading, a decline of 27% from the average daily volume of 45,279,406 shares. The stock had previously closed at $27.10.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong oncology franchise and pipeline could support upside around upcoming Q1 results — Pfizer has a deep, multi‑modality oncology portfolio (approved drugs + ADCs, small molecules, immuno‑oncology candidates) that investors view as a durable revenue and growth driver. How Pfizer’s Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: Ongoing R&D activity: Pfizer filed a new Phase 1 study (PF‑07328948), underscoring continued pipeline investment and potential future catalysts beyond established franchises. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Neutral Sentiment: Corporate housekeeping in India (Pfizer Limited) — a special window for dematerialisation of physical shares was announced; limited direct impact on NYSE-listed PFE. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: CEO Albert Bourla’s comments on global research competitiveness highlight strategic priorities but are not an immediate stock mover. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Neutral Sentiment: Sector and index movement are influencing PFE trading — some coverage points to S&P 500 correlation rather than company‑specific drivers. Pfizer Inc. (NYSE:PFE) Market Action Tied To S&P 500 Index Movement
• Negative Sentiment: Analyst pressure: RBC Capital reaffirmed a sell rating on PFE, and at least one analyst reiterated a bearish stance this week — analyst downgrades and negative notes can increase selling pressure. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, a near‑term pipeline disappointment that likely contributed to recent intraday weakness. The same coverage also flags Washington policy risk (reports of potential harsh tariffs on drugmakers without pricing deals) that could pressure margins and sentiment. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Recent price weakness noted across coverage — headlines pointing to PFE declines despite broader market gains highlight investor concern over the items above, amplifying volatility. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Guggenheim raised their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Morgan Stanley set a $27.00 price objective on Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Performance

The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $156.21 billion, a PE ratio of 20.20 and a beta of 0.43. The firm’s 50-day simple moving average is $27.14 and its two-hundred day simple moving average is $25.89.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the previous year, the company posted $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fiduciary Alliance LLC grew its holdings in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer during the 3rd quarter valued at $3,019,000. Vista Investment Partners LLC grew its holdings in shares of Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Money Concepts Capital Corp grew its holdings in shares of Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA purchased a new position in shares of Pfizer during the 3rd quarter valued at $16,613,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.